蒋芹 1张为民 1詹茂程 1吉亚君 1徐光辉 1卞宝祥1
作者信息
摘要
Abstract
Objective: This study was designed to investigate the chemotherapy effect of high-dose tamoxifen(TAM) in the patients with multidrug-resistant (MDR-1) non-small cell lung cancer(NSCLC). Methods: A total of 108 patients with refractory NSCLC were divided at random into four groups: A,B,C,and D. Each group contained 27 patients. A,B,and C were study group, D was control group. TAM was given from the third day before chemotherapy up to 11 days dose of TAM for group A: 40 mg, tid;group B: 60 mg, tid;group C: 80 mg, tid;group D: Simple chemotherapy. The dosage and schedule of the chemotherapy regimen was just same in every group: VDS 2.5 mg/m2 d1,d8, ADM 30 mg/m2 d2, DDP 80 mg/m2 d4,d5. The therapeutic effect of each group after having been performed 3 cyeles,and treatment rested 30 days was evaluated. Results:The response rates of the A,B,C,and D group were 33.3％ (9/27),48.1％ (13/27),55.6％ (15/27),25.9％ (7/27),respectively. The response rate of group C was the highest and group D was the lowest. Compared group A,B,C with group D,A∶ D P >0.05, the difference did not reach statistical significance;B∶ D P >0.05, the difference did not reach statistical significance;C∶ D P<0.05, the difference reached statistical significance. The major side effect of chemotherapy had not difference in every group. Only four patients of group C with TAM 240 mg/d developed psychiatric symptom, and TAM was abandoned after symptom automatic extinction. Conclusions: High dose TAM can be safely administered and may inhibit MDR-1 function. The dose of TAM become positive correlation to it's effect.关键词
难治性非小细胞肺癌/多药耐药/三苯氧胺分类
医药卫生
